Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCUN1D1 | Q96GG9 | 11/20 | 0.45 |
| ▸ | UBE2M | P61081 | 10/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5018681 | 1.00 | DCUN1D1 (0.45) | DCUN1D1UBE2MEPHX2GAAPSMB5 | |
| SCHEMBL5019161 | 1.00 | DCUN1D1 (0.45) | DCUN1D1UBE2MEPHX2GAAPSMB5 | |
| SCHEMBL5019162 | 0.92 | DCUN1D1 (0.46) | DCUN1D1UBE2MEPHX2PSMB5CCKBR | |
| SCHEMBL5024445 | 0.92 | DCUN1D1 (0.46) | DCUN1D1UBE2MEPHX2PSMB5CCKBR | |
| SCHEMBL5018626 | 0.92 | DCUN1D1 (0.46) | DCUN1D1UBE2MEPHX2PSMB5CCKBR | |
| Hydrochloric Acid SCHEMBL2749604 | 0.91 | DCUN1D1 (0.46) | DCUN1D1UBE2MEPHX2PSMB5CCKBR | |
| SCHEMBL5018475 | 0.90 | DCUN1D1 (0.44) | DCUN1D1UBE2MEPHX2PSMB5CCKBR | |
| SCHEMBL10271436 | 0.90 | DCUN1D1 (0.44) | DCUN1D1UBE2MEPHX2PSMB5CCKBR | |
| SCHEMBL5018451 | 0.90 | DCUN1D1 (0.44) | DCUN1D1UBE2MEPHX2PSMB5CCKBR | |
| Hydrochloric Acid SCHEMBL2747410 | 0.89 | DCUN1D1 (0.43) | DCUN1D1UBE2MEPHX2PSMB5CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178490-B2 | Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof | REMPEX PHARMACEUTICALS, INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| WO-2010054102-A2 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | MPEX PHARMACEUTICALS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152098-A1 | POLYBASIC BACTERIAL EFFLUX PUMP INHIBITORS AND THERAPEUTIC USES THEREOF | ABCB11, ABCB1, SLC47A1 | DCUN1D1 3227/4885UBE2M 1812/4885EPHX2 3088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.